MDxHealth SA (Euronext: MDXH.BR) held today its Annual General Shareholders' Meeting in Diegem. The shareholders approved all agenda items of the Annual General Shareholders' Meeting, including the financial statements for the financial year ended December 31, 2016.
In addition, the company held an Extraordinary General Shareholders' Meeting. As the required attendance quorum was not met for this meeting, a new Extraordinary General Shareholders' Meeting will be held on Monday June 19, 2017.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.